News Sentiment

SANA sentiment intelligence

Sana Biotechnology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.85 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 64

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-4.0% over one week, +43.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -4.0% Price reacting lower
Trend fit Trend inactive 43.7% over four weeks
Fair value -11.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 35
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 64
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 8
GlobeNewswire 5
simplywall.st 4
Quartr 3
Stock Titan 3
The National Law Review 3
Investing.com 3

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 21
Regulatory and legal 3
Analyst action 3
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 64
TradingView Direct company coverage

Sana Biotechnology, Inc. Stock 12‑Month Price Target Cut to $9.14, Implies 230% Upside

Sana Biotechnology, Inc.'s average 12-month price target has been lowered from $9.50 to $9.14 by 7 analysts, with individual forecasts ranging from $7 to $16 per share. This updated target suggests a potential upside of approximately 230% from its Jun. 11 closing price. Despite t

Tone
Positive 73/100
Event
Analyst action
Published
12 Jun 2026 04:09
Source
TradingView